Lupin launch a generic version of pain reliever for osteoarthritis in the US
Drug Approval

Lupin launch a generic version of pain reliever for osteoarthritis in the US

Ibuprofen and Famotidine tablets (Duexise) had estimated annual sales of US $ 765 million in the US as if July 21

  • By IPP Bureau | September 15, 2021

Pharma major Lupin announced the launch of the authorised generic version of Duexise (ibuprofen and famotidine) tablets, 800 mg/26.6 mg, of Horizon Medicines LLC.

Ibuprofen and Famotidine tablets, 800 mg/26.6 mg, are indicated for the relief of signs and symptoms of rheumatoid arthritis, osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as gastric and/or duodenal ulcer in patients who are taking ibuprofen for those indications.

Ibuprofen and Famotidine Tablets (RLD: Duexis) had estimated annual sales of US $ 765 million in the U.S. (IQVIA MAT July 2021).

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International